glp-1 insomnia Medications Show Promise as First Drug Therapy for Sleep Apnea Amazon.com: InnoSupps Night Shred GLP-1

Experts explain why hunger, food noise and other health changes return after stopping weight loss drugs and how to hold onto your progress.

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

Then came the duals (like #tirzepatide), and even triagonists (#retatrutide) that pushed weight loss even farther

Watch the discussion to learn how this broader approach could shape the next chapter of longevity science

quality standards, providing a safe and comprehensive approach to effective weight management and long-term metabolic health, designed to live in harmony with the body, not against it

Glucagon-like peptide-1 (GLP-1) receptor agonists have drawn a lot of interest lately for their therapeutic advantages over controlling blood sugar levels in the management of type 2 diabetes mellitus (T2DM)